PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS- A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1743
https://www.valueinhealthjournal.com/article/S1098-3015(18)35045-9/fulltext
Title :
PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS- A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35045-9&doi=10.1016/j.jval.2018.09.1743
First page :
Section Title :
Open access? :
No
Section Order :
1106